Trevi Therapeutics to Participate in Upcoming September Conferences

Trevi Therapeutics will join multiple September 2026 healthcare and investor events, offering fireside chats and scientific panels featuring its senior leadership.

Rhea-AI Summary

Trevi Therapeutics (TRVI) will participate in several healthcare and investor conferences in September 2026, featuring fireside chats and panel discussions in New York and Boston.

Events include the Cantor Global Healthcare Conference, H.C. Wainwright and Morgan Stanley healthcare conferences, and the 10th Anniversary IPF Summit, with company executives presenting and joining panels on IPF trials and development strategy.

Argus Sep 3 session 1 alert

+0.06% close to close 5.88K volume Open Argus

Details

News Market Reaction – TRVI

$2.31B Mkt Cap at Peak Alert

On Sep 3, the day this news came out, TRVI closed 0.06% above the previous close.

Data tracked by StockTitan Argus for the Sep 3 session.

Key Figures

Cantor conference dates: September 9-11, 2026 Cantor fireside chat: September 10, 10:55 a.m.-11:25 a.m. ET Wainwright conference dates: September 14-16, 2026 +5 more

Cantor conference dates

September 9-11, 2026

2026 Cantor Global Healthcare Conference

Cantor fireside chat

September 10, 10:55 a.m.-11:25 a.m. ET

2026 Cantor Global Healthcare Conference

Wainwright conference dates

September 14-16, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Wainwright fireside chat

September 14, 9:00 a.m.-9:30 a.m. ET

H.C. Wainwright 28th Annual Global Investment Conference

Morgan Stanley conference dates

September 14-16, 2026

Morgan Stanley 24th Annual Global Healthcare Conference

Morgan Stanley fireside chat

September 15, 4:50 p.m.-5:25 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference

IPF Summit dates

September 29-October 1, 2026

10th Anniversary IPF Summit

IPF Summit panels

October 1, 11:00-11:30 a.m. ET and 3:40-4:10 p.m. ET

10th Anniversary IPF Summit

Historical Context

5 past events · Latest: Aug 26

5 events

1. Aug 26

   ERS presentation announcement

   24h Move

   -0.2%

   Announced two chronic-cough abstracts for the 2026 ERS Congress

2. Aug 06

   2Q26 earnings report

   24h Move

   +0.1%

   Reported quarterly results and advanced multiple Haduvio clinical programs

3. Jul 30

   Earnings date announcement

   24h Move

   -0.8%

   Scheduled the second-quarter financial results and corporate update

4. Jul 28

   August conference schedule

   24h Move

   +1.7%

   Announced participation in two August biotech conferences

5. Jun 17

   June event schedule

   24h Move

   +6.3%

   Announced leadership participation in three industry events

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ipf, interstitial lung disease, patient-reported outcomes

3 terms

ipf medical

"for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where scar tissue builds up in the lungs for reasons doctors don't fully understand, making it harder to breathe over time. For investors, IPF matters because it represents a clear medical need and a regulated market for treatments, so progress in clinical trials, regulatory approvals, or new therapies can materially affect the value of companies working on drugs or devices for this condition—much like a new road that could open access to a previously hard-to-reach town.

interstitial lung disease medical

"non-IPF interstitial lung disease (non-IPF ILD)"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

patient-reported outcomes medical

"Which Patient-Reported Outcomes Should We Use in IPF Trials and Care"

Reports provided directly by patients about their symptoms, daily functioning, and quality of life—collected through surveys, apps, or interviews—reflecting how a treatment affects real people rather than lab measures. Investors care because these firsthand accounts help regulators, doctors and payers judge a product’s real-world value and can influence approval, pricing, adoption and long-term sales; think of them as customer reviews that show whether a medical product truly improves everyday life.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September.

2026 Cantor Global Healthcare Conference
September 9-11, 2026, New York, New York
Fireside Chat: September 10, 10:55 a.m. to 11:25 a.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFO
To register for the Fireside Chat virtually, click here.

H.C. Wainwright 28th Annual Global Investment Conference
September 14-16, 2026, New York, New York
Fireside Chat (in-person): September 14, 9:00 a.m. to 9:30 a.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Morgan Stanley 24th Annual Global Healthcare Conference
September 14-16, 2026, New York, New York
Fireside Chat: September 15, 4:50 p.m. to 5:25 p.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO
To register for the Fireside Chat virtually, click here.

10th Anniversary IPF Summit
September 29-October 1, 2026, Boston, Massachusetts
Panel Discussions: October 1, 11:00 a.m. to 11:30 a.m. ET and 3:40 p.m. to 4:10 p.m. ET
Panel 1: Which Patient-Reported Outcomes Should We Use in IPF Trials and Care to Ensure We’re Measuring What Matters to Patients
Panel 2: Translating Preclinical Combination Data into Clinical Development Strategy
Trevi Representative: James Cassella, Ph.D., CDO
To register for the summit, click here.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Trevi Therapeutics (TRVI) appear at the 2026 Cantor Global Healthcare Conference?

Trevi Therapeutics will participate in the 2026 Cantor Global Healthcare Conference in New York, NY from September 9–11, 2026. A fireside chat is scheduled for September 10 from 10:55 a.m. to 11:25 a.m. ET.

Who will represent Trevi Therapeutics (TRVI) at the Cantor Global Healthcare Conference fireside chat?

The Cantor fireside chat will feature Jennifer Good, President and CEO, and David Hastings, CFO of Trevi Therapeutics.

What is Trevi Therapeutics’ schedule at the H.C. Wainwright 28th Annual Global Investment Conference for TRVI?

Trevi will attend the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY from September 14–16, 2026. An in-person fireside chat is set for September 14 from 9:00 a.m. to 9:30 a.m. ET.

Who will speak for Trevi Therapeutics (TRVI) at the H.C. Wainwright 2026 fireside chat?

The H.C. Wainwright fireside chat will include Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO of Trevi Therapeutics.

What is Trevi Therapeutics’ participation in the Morgan Stanley 24th Annual Global Healthcare Conference for TRVI?

Trevi will take part in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY from September 14–16, 2026. A fireside chat is scheduled for September 15 from 4:50 p.m. to 5:25 p.m. ET.

Who represents Trevi Therapeutics (TRVI) at the Morgan Stanley Global Healthcare Conference fireside chat?

The Morgan Stanley fireside chat will feature Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO of Trevi Therapeutics.

How is Trevi Therapeutics (TRVI) involved in the 10th Anniversary IPF Summit in 2026?

Trevi will participate in the 10th Anniversary IPF Summit in Boston, MA from September 29–October 1, 2026. On October 1, CDO James Cassella, Ph.D. will join two 30-minute panel discussions on IPF patient-reported outcomes and translating preclinical combination data into clinical strategy.